Literature DB >> 29059312

Conjunctival Melanoma in Chinese Patients: Local Recurrence, Metastasis, Mortality, and Comparisons With Caucasian Patients.

Chuandi Zhou1, Yuxin Wang1, Renbing Jia1, Xianqun Fan1.   

Abstract

Purpose: To evaluate the prognosis in Chinese patients with conjunctival melanoma and determine its predictors. Further, to explore the racial differences in clinical characteristics and outcomes between Chinese and Caucasian patients.
Methods: This cohort study included 57 eyes of 57 consecutive patients with pathologically verified conjunctival melanoma between 1996 and 2016. Medical records were reviewed for factors associated with the local recurrence, metastasis, and tumor-related mortality. All eligible patients were followed up for these three outcome measures. The demographic data, clinical characteristics, and outcomes were compared between Chinese and Caucasian patients.
Results: The mean follow-up period was 52.2 ± 49.4 months. Among the total 57 patients, 29 (51%) patients experienced local recurrence. The 1-, 5-, and 10-year recurrence rate was 31.0%, 59.7%, and 66.4%, respectively. Treatment complications detected in the follow-up included dry eye (32, 56.1%), irregular eyelid margin (25, 43.9%), eyelid retraction (18, 31.6%), blepharoptosis (9, 15.8%), mixed pigmentation of the tarsus reconstructed by mucosal membrane graft, corneal opacities (6, 10.5%), and symblepharon (2, 3.5%). Twenty (35%) patients developed metastasis. The 1-, 5-, and 10-year metastasis rate was 16.7%, 38.7%, and 50.9%, respectively. Fourteen (25%) patients died of conjunctival melanoma, with a median survival time of 24 months. The 1-, 5-, and 10-year tumor-related mortality was 3.8%, 30.5%, and 37.4%, respectively. Tumor hemorrhage is an independent risk factor for tumor-related death (hazard ratio [HR]: 18.81, P = 0.01) and metastasis (HR: 4.57, P = 0.02). Significant differences were noted between Chinese and Caucasians patients from America, Germany, and England in demographics, clinical characteristics, and outcomes. Compared to Caucasians, Chinese patients tended to have more male cases (P < 0.01) and to be younger (P = 0.03). At initial presentation, more Chinese patients had de novo tumor origin (P < 0.01), epithelioid cell type (P < 0.01), nonbulbar tumor location (P < 0.01), greater basal diameter (P = 0.04), multifocal tumor (P < 0.01), feeder vessels (P < 0.01), eyelid (P < 0.01) and orbit involvement (P < 0.01), and advanced T stages (P < 0.01). Over a similar follow-up period with Caucasians patients (52.2 vs. 52 months, P = 0.97), a significantly larger proportion of Chinese patients exhibited eyelid invasion (P = 0.04) and orbital invasion (P < 0.01) at follow-up, local recurrence (P < 0.01), metastasis (P < 0.01), and tumor-related death (P < 0.01). Conclusions: Conjunctival melanoma is a rare malignancy with great potential for mortality in Chinese. Special attention should be paid to patients with tumor hemorrhage. Compared to Caucasians, Chinese patients exhibit more aggressive clinical signs with compromised prognosis.

Entities:  

Mesh:

Year:  2017        PMID: 29059312     DOI: 10.1167/iovs.17-22376

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  m6A RNA hypermethylation-induced BACE2 boosts intracellular calcium release and accelerates tumorigenesis of ocular melanoma.

Authors:  Fanglin He; Jie Yu; Jie Yang; Shaoyun Wang; Ai Zhuang; Hanhan Shi; Xiang Gu; Xiaofang Xu; Peiwei Chai; Renbing Jia
Journal:  Mol Ther       Date:  2021-02-15       Impact factor: 12.910

2.  Fangchinoline suppresses conjunctival melanoma by directly binding FUBP2 and inhibiting the homologous recombination pathway.

Authors:  Keting Bao; Yongyun Li; Jinlian Wei; Ruoxi Li; Jie Yang; Jiahao Shi; Baoli Li; Jin Zhu; Fei Mao; Renbing Jia; Jian Li
Journal:  Cell Death Dis       Date:  2021-04-07       Impact factor: 8.469

3.  Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study.

Authors:  Puneet Jain; Paul T Finger; Maria Fili; Bertil Damato; Sarah E Coupland; Heinrich Heimann; Nihal Kenawy; Niels J Brouwer; Marina Marinkovic; Sjoerd G Van Duinen; Jean Pierre Caujolle; Celia Maschi; Stefan Seregard; David Pelayes; Martin Folgar; Yacoub A Yousef; Hatem Krema; Brenda Gallie; Alberto Calle-Vasquez
Journal:  Br J Ophthalmol       Date:  2020-09-05       Impact factor: 4.638

4.  The Clinical Feature and Treatment Outcome of Ocular Melanoma: A 34-Year Experience in a Tertiary Referral Center.

Authors:  Yu-Yun Huang; Tzu-Yu Hou; Wei-Kuang Yu; Chieh-Chih Tsai; Shu-Ching Kao; Wen-Ming Hsu; Jui-Ling Catherine Liu
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639

5.  Publication trends of research on conjunctival melanoma during 1997-2022: A 25-year bibliometric study.

Authors:  Wei Xu; Ludi Yang; Shengfang Ge; Shichong Jia; Fen Gu
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

6.  Conjunctival pigmented lesion: Clinicopathological analysis of 85 cases in Korean population.

Authors:  Yun Jeong Lee; Cheol Lee; Mee Kum Kim; Sang In Khwarg; Joo Youn Oh
Journal:  Sci Rep       Date:  2019-12-03       Impact factor: 4.379

7.  Clinical features and survival outcomes of ocular melanoma in a multi-ethnic Asian cohort.

Authors:  Laura Ling Ying Tan; Jiancheng Hong; Wei Lin Goh; Esther Wei Yin Chang; Valerie Shiwen Yang; Eileen Poon; Nagavalli Somasundaram; Mohamad Farid; Anita Sook Yee Chan; Jason Yongsheng Chan
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.